Vaxart, Inc. (VXRT)

↓ Download CSV

CIK 0000072444 · OTC · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Vaxart, Inc. reported revenue of $237.26M, up 726.7% from the prior year. The company was profitable, with a net margin of 6.9%. It held $186.08M in total assets against $98.28M in total liabilities.

Key ratios (FY2025)

7.6%
Operating margin
6.9%
Net margin
18.6%
Return on equity
+726.7%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$237.26M$28.70M$7.38M$4.16M$5.84M$9.30M
Operating Income$18.07M-$66.29M-$83.35M-$114.59M-$72.75M-$30.17M-$15.79M-$21.76M-$10.02M-$25.20M
Net Income$16.33M-$66.95M-$82.47M-$107.76M-$70.47M-$32.22M-$18.64M-$18.01M-$9.58M-$25.40M
EPS (Diluted)$0.07$-0.33$-0.57$-0.84$-0.58$-0.76$-0.66
Total Assets$186.08M$166.39M$91.83M$153.85M$221.17M$152.58M$37.03M$35.23M$4.52M$72.70M
Total Liabilities$98.28M$107.46M$34.02M$43.25M$33.64M$29.18M$24.08M$23.99M$43.24M$26.50M
Shareholders' Equity$87.80M$58.92M$57.80M$110.60M$187.53M$123.40M$12.95M$11.21M-$38.72M-$29.64M
Cash & Equivalents$34.76M$44.01M$143.75M$11.51M$1.57M$8.40M
Operating Cash Flow$7.71M-$44.76M-$70.45M-$94.78M-$59.83M-$23.75M-$13.09M-$14.55M-$10.04M
Capital Expenditures$145.0K$554.0K$1.87M$9.60M$5.16M$1.22M$850.0K$707.0K$117.0K$200.0K
Shares Outstanding240.49M227.77M153.45M134.20M125.59M110.27M48.25M7.14M138.5K38.64M